Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance …
DAI Dong, XU Wengui, W Qi, LI Xiaofeng… - Zhongguo Fei Ai …, 2017 - search.proquest.com
肺癌 80% 以上为非小细胞肺癌 (non-small cell lung cancer, NSCLC), 表皮生长因子受体
(epidermal growth factor receptor, EGFR) 介导的信号通路与 NSCLC 发生发展密切相关. 针对 …
(epidermal growth factor receptor, EGFR) 介导的信号通路与 NSCLC 发生发展密切相关. 针对 …
George de Hevesy in America
WC Klingensmith, JR Osborne - Journal of Nuclear Medicine, 2020 - Soc Nuclear Med
TO THE EDITOR: George de Hevesy was a Hungarian radiochemist who was awarded the
Nobel Prize in Chemistry in 1943 for the discovery of the radiotracer principle (1). As the …
Nobel Prize in Chemistry in 1943 for the discovery of the radiotracer principle (1). As the …
The use of PET/CT imaging data for a mechanistic PK model of radiolabeled temozolomide.
Z Amiri - 2021 - studenttheses.uu.nl
Background Temozolomide is a chemotherapeutic drug that is currently dosed according to
the body surface area (BSA) in malignant gliomas. Although effective, many patients stop …
the body surface area (BSA) in malignant gliomas. Although effective, many patients stop …
Molecular imaging applications of antibody-based immunotherapeutics to understand cancer drug distribution
S Waaijer - 2020 - research.rug.nl
With the landscape-transforming arrival of cancer immunotherapy, such as drugs that block
immune checkpoints, durable responses are observed for several different cancer types …
immune checkpoints, durable responses are observed for several different cancer types …
[PDF][PDF] George de Hevesy in America
G de Hevesy - THE JOURNAL OF NUCLEAR MEDICINE, 2020 - scholar.archive.org
TO THE EDITOR: George de Hevesy was a Hungarian radiochemist who was awarded the
Nobel Prize in Chemistry in 1943 for the discovery of the radiotracer principle (1). As the …
Nobel Prize in Chemistry in 1943 for the discovery of the radiotracer principle (1). As the …
ABCG2-and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases
EA van de Stadt, M Yaqub, I Bahce… - Journal of Nuclear …, 2020 - Soc Nuclear Med
TO THE EDITOR: We read with great interest the article by Bauer et al. titled ''A Proof-of-
Concept Study to Inhibit ABCG2-and ABCB1-Mediated Efflux Transport at the Human Blood …
Concept Study to Inhibit ABCG2-and ABCB1-Mediated Efflux Transport at the Human Blood …
Application of Quantitative Metrics for EGFR-Targeted Non-Small Cell Lung Cancer Therapy Using [11C] Erlotinib PET
JR Petrulli - 2017 - search.proquest.com
Non-small cell lung cancer (NSCLC) is one of the leading causes of death in the world.
Within recent years, a popular treatment for NSCLC using drugs known as tyrosine kinase …
Within recent years, a popular treatment for NSCLC using drugs known as tyrosine kinase …
Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer
LUO Danjing, MA Jin'an, J ZHANG… - Zhongguo Fei Ai Za …, 2017 - search.proquest.com
靶向药物表皮生长因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor tyrosine
kinase inhibitor, EGFR-TKI) 改变了非小细胞肺癌的治疗格局, 研究表明只有 EGFR …
kinase inhibitor, EGFR-TKI) 改变了非小细胞肺癌的治疗格局, 研究表明只有 EGFR …
[PDF][PDF] Personalizing NSCLC therapy by characterizing tumors
IBMYEF Smit, AA Lammertsma - development, 2013 - cyberleninka.org
Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of
precision medicine with an ever increasing number of drugs directed against a variety of …
precision medicine with an ever increasing number of drugs directed against a variety of …